≥2 well-powered RCTs in humans with consistent effect size. Plausible mechanism. No major contradictory data.
| # | Compound | Category | EU Status | Last reviewed |
|---|---|---|---|---|
| 001. | Bremelanotide INN · bremelanotidum Melanocortin (MC1R/MC3R/MC4R) receptor agonist · on-demand subcutaneous | Hormonal | NOT AUTHORISED | 18 MAY 2026 |
| 002. | Setmelanotide INN · setmelanotidum MC4R-selective melanocortin receptor agonist · daily subcutaneous | Hormonal | AUTHORISED | 18 MAY 2026 |
| 003. | Tesamorelin INN · tesamorelinum Synthetic GHRH analogue · stimulates pituitary GH release · daily subcutaneous | Metabolic | AUTHORISED | 18 MAY 2026 |